CENTOGENE News & Events Header Image Broschure

News

Stay up to date and read about our most recent milestones towards achieving CENTOGENE’s mission: To enable the cure of 100 rare diseases in 10 years.

Interested in receiving the latest news around the clock? Follow us on LinkedIn.

Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and neurodegenerative diseases, today announced…

Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and neurodegenerative diseases, today announced…

Interim CFO Miguel Coego Rios appointed as Managing Director and permanent CFO. Centogene N.V. today announced the appointment of Miguel Coego Rios as…

Centogene N.V. today announced the voting results of the Company’s Annual General Meeting. Shareholders voted in favor of all proposals, which…

Working together on the world’s first treatment that targets the underlying causes of pyruvate kinase (“PK”) deficiency in children under the age of…

CE-marked clinical decision support platform enables laboratories to provide best-in-class diagnostics of genetic diseases

Newly established WGS recommendations published in the European Journal of Human Genetics

Company management will present in the virtual track at the H.C. Wainwright Global Investment Conference being held May 23–26, 2022, and invites…

Accelerating the path from diagnosis to available treatments for rare metabolic and rare neurodegenerative diseases

Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases,…

For Further Inquiries Please Contact

Press Contact

Ben Legg

Corporate Communications

Email Us

Downloads

Here you can find forms, brochures, flyer and information sheets for download (PDF) about the broad genetic testing product and service portfolio of CENTOGENE.

Downloads